VYGR RSI Chart
Last 7 days
-12.2%
Last 30 days
-14.0%
Last 90 days
9.3%
Trailing 12 Months
0.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 93.2M | 145.5M | 197.7M | 250.0M |
2022 | 38.3M | 39.2M | 40.0M | 40.9M |
2021 | 159.6M | 132.2M | 15.9M | 37.4M |
2020 | 117.3M | 99.9M | 197.3M | 171.1M |
2019 | 11.9M | 55.4M | 73.7M | 104.4M |
2018 | 9.6M | 11.0M | 12.0M | 7.6M |
2017 | 10.9M | 8.3M | 6.2M | 10.1M |
2016 | 19.6M | 18.4M | 16.8M | 14.2M |
2015 | 0 | 0 | 0 | 17.3M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 02, 2024 | sandrock alfred | sold | -119,454 | 9.86 | -12,115 | president and ceo |
Apr 02, 2024 | swartz robin | sold | -13,407 | 9.88 | -1,357 | chief operating officer |
Apr 01, 2024 | ferguson toby | acquired | - | - | 105,000 | chief medical officer |
Feb 21, 2024 | carter todd alfred | sold | -25,136 | 7.47 | -3,365 | chief scientific officer |
Feb 21, 2024 | sandrock alfred | sold | -97,226 | 7.46 | -13,033 | president and ceo |
Feb 21, 2024 | pfreundschuh peter p. | sold | -28,079 | 7.46 | -3,764 | chief financial officer |
Feb 21, 2024 | swartz robin | sold | -29,546 | 7.45 | -3,966 | chief operating officer |
Feb 20, 2024 | carter todd alfred | sold | -4,623 | 7.68 | -602 | chief scientific officer |
Feb 09, 2024 | carter todd alfred | acquired | - | - | 38,500 | chief scientific officer |
Feb 09, 2024 | swartz robin | acquired | - | - | 50,000 | chief operating officer |
Which funds bought or sold VYGR recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 05, 2024 | GAMMA Investing LLC | added | 33.56 | 770 | 1,853 | -% |
Apr 05, 2024 | CWM, LLC | added | 88.35 | 10,000 | 20,000 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 1.92 | 2,115,230 | 21,350,400 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 155 | 1,945,150 | 3,038,820 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.4 | 10,397 | 133,242 | -% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | reduced | -14.42 | -619,000 | 8,481,000 | -% |
Feb 15, 2024 | Legal & General Group Plc | unchanged | - | 2,974 | 36,360 | -% |
Feb 15, 2024 | State of Wyoming | added | 29.62 | 65,444 | 224,428 | 0.04% |
Feb 15, 2024 | BARCLAYS PLC | added | 261 | 418,000 | 559,000 | -% |
Feb 14, 2024 | Voya Investment Management LLC | unchanged | - | 9,155 | 111,982 | -% |
Unveiling Voyager Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Voyager Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 39.7B | 6.8B | -8.41 | 5.79 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.5B | 1.8B | -42.01 | 10.12 | ||||
BMRN | 17.2B | 2.4B | 102.31 | 7.09 | ||||
INCY | 11.9B | 3.7B | 20 | 3.23 | ||||
MID-CAP | ||||||||
APLS | 6.2B | 396.6M | -11.82 | 15.75 | ||||
BBIO | 4.4B | - | -6.81 | 60.35 | ||||
AXSM | 3.3B | 270.6M | -13.62 | 12.04 | ||||
ARWR | 2.9B | 240.7M | -9.88 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.95 | 3.88 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 25.63 | 4.6 | ||||
NVAX | 557.0M | 983.7M | -1.02 | 0.57 | ||||
CRBP | 432.8M | 881.7K | -9.7 | 466.16 | ||||
INO | 225.3M | 4.9M | -1.67 | 46.29 | ||||
IBIO | 6.8M | 2.1M | -0.25 | 2.14 |
Voyager Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 1851.9% | 90,061 | 4,614 | 4,853 | 150,480 | 95,783 | 41,086 | 36,749 | 32,411 | 28,074 | 1,482 | 1,357 | 6,501 | 6,537 | 117,843 | 28,681 | 18,067 | 32,674 | 20,433 | 46,087 | 5,197 | 2,008 |
Operating Expenses | 5.5% | 35,998 | 34,121 | 30,279 | 27,596 | 23,013 | 26,644 | 20,079 | 22,008 | 22,372 | 26,628 | 29,942 | 32,090 | 30,266 | 33,316 | 37,662 | 42,500 | 46,442 | 38,240 | 36,898 | 34,490 | 25,169 |
S&GA Expenses | 24.0% | 10,242 | 8,258 | 8,294 | 9,028 | 8,462 | 7,307 | 7,552 | 7,659 | 8,351 | 8,714 | 10,437 | 9,744 | 8,270 | 8,277 | 8,239 | 10,206 | 9,891 | 8,463 | 8,322 | 9,659 | 8,256 |
R&D Expenses | -0.4% | 25,756 | 25,863 | 21,985 | 18,568 | 14,551 | 19,337 | 12,527 | 14,349 | 14,021 | 17,914 | 19,505 | 22,346 | 21,997 | 25,039 | 29,423 | 32,294 | 36,551 | 29,777 | 28,576 | 24,831 | 16,914 |
EBITDA Margin | 92.2% | 0.55* | 0.29* | 0.69* | 1.12* | -0.98* | -1.61* | -1.65* | -1.68* | -1.76* | 2.61* | 0.31* | 0.26* | - | - | - | - | - | - | - | - | - |
Income Taxes | 564.4% | 822 | -177 | 59.00 | 704 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | 319.4% | 57,217 | -26,078 | -22,149 | 124,748 | -23,610 | 17,624 | -19,087 | -21,319 | - | - | - | - | - | - | - | - | -12,574 | -15,006 | 11,153 | -27,170 | -22,531 |
EBT Margin | 99.9% | 0.53* | 0.27* | 0.66* | 1.07* | -1.13* | -1.78* | -1.82* | -1.86* | -1.90* | 2.31* | 0.28* | 0.23* | - | - | - | - | - | - | - | - | - |
Net Income | 317.7% | 56,395 | -25,901 | -22,208 | 124,044 | -23,626 | 17,624 | -19,087 | -21,319 | 5,709 | -25,137 | -30,120 | -21,649 | -15,926 | 85,611 | -8,681 | -24,263 | -12,574 | -15,006 | 11,153 | -27,170 | -22,532 |
Net Income Margin | 100.1% | 0.53* | 0.26* | 0.66* | 1.06* | -1.13* | -0.43* | -1.53* | -1.85* | -1.90* | -5.85* | 0.14* | 0.25* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -12.3% | -24,515 | -21,833 | -2,045 | 123,056 | -13,177 | -16,484 | -19,727 | 34,388 | 10,848 | -21,369 | -22,944 | -21,669 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | 19.2% | 351 | 295 | 316 | 336 | 159 | 182 | 189 | 224 | 194 | 185 | 209 | 238 | 262 | 270 | 297 | 323 | 355 | 376 | 389 | 411 | 177 |
Current Assets | 22.1% | 320 | 262 | 282 | 303 | 124 | 147 | 152 | 171 | 137 | 126 | 149 | 176 | 198 | 216 | 247 | 272 | 305 | 328 | 341 | 365 | 162 |
Cash Equivalents | 5.4% | 69.00 | 65.00 | 244 | 268 | 99.00 | 98.00 | 80.00 | 132 | 117 | 113 | 120 | 118 | 106 | 149 | 146 | 165 | 87.00 | 83.00 | 81.00 | 113 | 48.00 |
Net PPE | -3.6% | 16.00 | 17.00 | 17.00 | 17.00 | 18.00 | 18.00 | 19.00 | 19.00 | 22.00 | 23.00 | 24.00 | 25.00 | 25.00 | 23.00 | 20.00 | 19.00 | 18.00 | 15.00 | 14.00 | 13.00 | 13.00 |
Liabilities | -2.9% | 115 | 118 | 117 | 119 | 100 | 103 | 129 | 148 | 99.00 | 97.00 | 98.00 | 102 | 107 | 104 | 221 | 243 | 255 | 268 | 270 | 311 | 131 |
Current Liabilities | 4.6% | 65.00 | 62.00 | 45.00 | 20.00 | 73.00 | 73.00 | 98.00 | 102 | 51.00 | 27.00 | 25.00 | 25.00 | 27.00 | 42.00 | 68.00 | 73.00 | 76.00 | 80.00 | 69.00 | 59.00 | 32.00 |
Shareholder's Equity | 34.1% | 236 | 176 | 199 | 217 | 59.00 | 80.00 | 60.00 | 76.00 | 95.00 | 87.00 | 111 | 136 | 154 | 166 | 77.00 | 80.00 | 100 | 108 | 118 | 101 | 46.00 |
Retained Earnings | 17.8% | -261 | -317 | -291 | -269 | -393 | -369 | -387 | -368 | -347 | -352 | -327 | -297 | -275 | -259 | -345 | -336 | -312 | -300 | -285 | -296 | -269 |
Additional Paid-In Capital | 0.7% | 498 | 494 | 491 | 487 | 453 | 450 | 448 | 445 | 442 | 440 | 438 | 434 | 430 | 426 | 422 | 416 | 412 | 408 | 403 | 397 | 316 |
Shares Outstanding | 0.3% | 44.00 | 44.00 | 44.00 | 43.00 | 39.00 | 39.00 | 38.00 | 38.00 | 38.00 | 38.00 | 38.00 | 38.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 489 | - | - | - | 114 | - | - | - | 103 | - | - | - | 292 | - | - | - | 686 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -12.9% | -23,760 | -21,051 | -835 | 123,565 | -12,244 | -16,206 | -18,485 | 34,426 | 11,195 | -20,709 | -22,717 | -21,294 | -21,977 | -24,740 | -21,201 | -28,798 | -23,360 | -21,579 | -31,557 | 125,162 | -24,348 |
Share Based Compensation | 5.8% | 3,045 | 2,878 | 2,672 | 2,558 | 2,346 | 2,189 | 2,490 | 2,319 | 1,654 | 2,078 | 3,991 | 3,601 | 3,502 | 3,532 | 3,860 | 4,040 | 3,520 | 3,349 | 5,253 | 3,518 | 2,638 |
Cashflow From Investing | 117.0% | 26,833 | -158,304 | -24,663 | 14,491 | 14,067 | 34,722 | -36,130 | -19,998 | -5,464 | 14,340 | 22,405 | 34,625 | -21,516 | 27,356 | -1,838 | 108,993 | 26,462 | 22,610 | -2,888 | -136,661 | 28,630 |
Cashflow From Financing | 39.0% | 460 | 331 | 1,548 | 31,306 | 276 | 15.00 | 807 | 12.00 | 227 | - | 357 | 28.00 | 486 | 510 | 2,133 | 34.00 | 300 | 1,724 | 1,069 | 77,901 | 435 |
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Consolidated Statements of Operations and Comprehensive Income (Loss) | |||
Collaboration revenue | $ 250,008 | $ 40,907 | $ 37,415 |
Operating expenses: | |||
Research and development | 92,172 | 60,764 | 73,787 |
General and administrative | 35,822 | 30,980 | 37,246 |
Total operating expenses | 127,994 | 91,744 | 111,033 |
Operating income (loss) | 122,014 | (50,837) | (73,618) |
Other income, net: | |||
Interest income (expense) | 11,721 | 1,792 | (390) |
Other income | 3 | 2,653 | 2,811 |
Total other income, net | 11,724 | 4,445 | 2,421 |
Income (loss) before income taxes | 133,738 | (46,392) | (71,197) |
Income tax provision | 1,408 | 16 | |
Net income (loss) | 132,330 | (46,408) | (71,197) |
Other comprehensive income (loss) | |||
Net unrealized gain (loss) on available-for-sale-securities | 171 | (81) | (4) |
Total other comprehensive income (loss) | 171 | (81) | (4) |
Comprehensive income (loss) | $ 132,501 | $ (46,489) | $ (71,201) |
Net income (loss) per share, basic | $ 3.08 | $ (1.21) | $ (1.89) |
Net income (loss) per share, diluted | $ 2.97 | $ (1.21) | $ (1.89) |
Weighted-average common shares outstanding, basic | 43,020,747 | 38,356,810 | 37,668,947 |
Weighted-average common shares outstanding, diluted | 44,569,334 | 38,356,810 | 37,668,947 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 68,802 | $ 98,959 |
Marketable securities | 162,073 | 19,889 |
Accounts receivable | 80,150 | |
Related party collaboration receivable | 3,341 | 257 |
Prepaid expenses and other current assets | 5,318 | 5,394 |
Total current assets | 319,684 | 124,499 |
Property and equipment, net | 16,494 | 17,857 |
Deposits and other non-current assets | 1,593 | 1,515 |
Operating lease, right-of-use assets | 13,510 | 15,485 |
Total assets | 351,281 | 159,356 |
Current liabilities: | ||
Accounts payable | 1,604 | 2,566 |
Accrued expenses | 16,823 | 7,816 |
Other current liabilities | 3,200 | 2,832 |
Deferred revenue, current | 42,881 | 59,377 |
Total current liabilities | 64,508 | 72,591 |
Deferred revenue, non-current | 32,359 | 6,450 |
Other non-current liabilities | 18,094 | 21,295 |
Total liabilities | 114,961 | 100,336 |
Commitments, contingencies, and other liabilities (see note 8) | ||
Stockholders' equity: | ||
Preferred stock, $0.001 par value: 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022 | ||
Common stock, $0.001 par value: 120,000,000 shares authorized; 44,038,333 and 38,613,891 shares issued and outstanding at December 31, 2023 and 2022, respectively | 44 | 38 |
Additional paid-in capital | 497,506 | 452,713 |
Accumulated other comprehensive loss | (48) | (219) |
Accumulated deficit | (261,182) | (393,512) |
Total stockholders' equity | 236,320 | 59,020 |
Total liabilities and stockholders' equity | $ 351,281 | $ 159,356 |